| 摘要 |
［Objectives］ To observe the clinical efficacy of external application of Scorzonera Herpes Ointment combined with Methylprednisolone Sodium Succinate for Injection in the treatment of herpes zoster oticus (HZO). [Methods] A total of 100 HZO patients admitted to the 988th Hospital of the Joint Logistics Support Force and Henan Provincial People’s Hospital from June 2021 to June 2023 were selected. They were divided into a treatment group and a control group using a random number table method, with 50 cases in each group. Both groups received Methylprednisolone Sodium Succinate for Injection. Additionally, the treatment group was treated with external application of Scorzonera Herpes Ointment, while the control group received acyclovir ointment. Both groups were treated for 10 d. The comparisons included clinical efficacy, total symptom and sign scores, pain level [Visual Analogue Scale (VAS)], time for erythema reduction, cessation of blister formation, scab formation, and scab shedding, incidence of post-herpetic neuralgia (PHN), air conduction hearing threshold, and air-bone gap. [Results] After 10 d of treatment, the total effective rate was 98.00% (49/50) in the treatment group and 84.00% (42/50) in the control group, with a statistically significant difference between the two groups (P<0.05). After 10 d of treatment, the total symptom and sign scores and VAS scores of both groups decreased compared to those before treatment. The treatment group had significantly lower scores than the control group (P<0.05). The treatment group showed significantly shorter time for erythema reduction, cessation of blister formation, scab formation, and scab shedding compared to the control group (P<0.05). During the 1-month follow-up after treatment, no PHN cases occurred in the treatment group, while the incidence of PHN in the control group was 24.00% (12/50), showing a statistically significant difference (P<0.05). After 10 d of treatment, both groups showed reduced air conduction hearing thresholds, and the treatment group exhibited significantly lower air conduction thresholds and air-bone gaps compared to the control group (P<0.05). No statistically significant difference was observed in the air-bone gap before and after treatment in the control group (P>0.05). [Conclusions] The combination of external application of Scorzonera Herpes Ointment and Methylprednisolone Sodium Succinate for Injection can alleviate pain and other discomforts, reduce PHN incidence, shorten disease duration, and improve hearing in HZO patients. |
